Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
LMO2
REST API REST API
Homo sapiens
LMO2 is differentially expressed in 308 experiments: 118 organism parts: lung, blood, ... (116 more);, 221 disease states: normal, chronic myelogenous leukemia, ... (219 more);, 121 cell types 365 cell lines 42 compound treatments and 80 other conditions.
Synonyms RHOM2, RBTNL1, TTG2, RBTN2
Orthologs Lmo2 (Rattus norvegicus)   RBTN2_BOVIN (Bos taurus)   Q71LH8_CHICK (Gallus gallus)   Bx (Drosophila melanogaster)   Lmo2 (Mus musculus)   lmo2 (Danio rerio)   lmo2 (Xenopus laevis)   LMO2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, protein binding, protein complex, metal ion binding, positive regulation of transcription from RNA polymerase II promoter, multicellular organismal development, nucleus, chromatin binding, zinc ion binding, negative regulation of erythrocyte differentiation
InterPro Term Znf_LIM
UniProt Accession P25791
Search EB-eye ENSG00000135363
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, ... (32 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (36 experiments)

Factor Value U/D Experiments
HL-60
4
E-GEOD-5258, E-MTAB-37, E-GEOD-24147, E-GEOD-96
SW480
4
E-MTAB-37, E-GEOD-18005, E-MEXP-1014, E-GEOD-2509
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
MCF-7
2
E-GEOD-20081, E-GEOD-19639
MOLT4
2
E-MTAB-37, E-MTAB-62
T84
2
E-MTAB-37, E-GEOD-1474
359 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (57 experiments)

Factor Value U/D Experiments
endothelial cell
1
3
E-GEOD-3920, E-GEOD-19240, E-GEOD-96, E-GEOD-3998
human foreskin fibroblast
2
E-GEOD-18147, E-GEOD-18265
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
centroblast
2
E-TABM-702, E-GEOD-15271
115 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-TABM-15, E-GEOD-16363, E-MTAB-62, ... (66 experiments)

Factor Value U/D Experiments
chronic myelogenous leukemia
4
E-MTAB-37, E-MTAB-62, E-GEOD-5550, E-GEOD-96
lung adenocarcinoma
4
E-GEOD-2514, E-MEXP-231, E-MTAB-37, E-MTAB-62
AIDS-KS, HIV+, nodular (late) stage
2
E-MEXP-66, E-MTAB-62
acute quadriplegic myopathy
2
E-GEOD-3307, E-MTAB-62
cervical carcinoma
2
E-MTAB-62, E-GEOD-5823
colon carcinoma
2
E-MTAB-62, E-MTAB-37
215 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5542, E-TABM-782, E-TABM-868, E-MEXP-2590, ... (26 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
heregulin
1
E-GEOD-6462
Cxcl12
1
1
E-GEOD-7307
interleukin-4 (Homo sapiens) + anti-CD40
1
E-GEOD-7307
dexamethasone/8-bromo cyclic AMP/isobutylmethylxanthine (DCI)
1
E-GEOD-3306
HMB-PP (phosphoantigen)
1
E-MEXP-1601
36 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-4922

Factor Value U/D Experiments
86
1
1
E-GEOD-3494
86 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-1140, E-MEXP-1251, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-MEXP-2359, E-GEOD-6236, E-MEXP-2283, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-GEOD-2509, E-TABM-147, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-4086

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-GEOD-7578, E-MTAB-108, E-GEOD-6431, ... (6 experiments)

Genotype
studied in E-GEOD-1045, E-MEXP-1996, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (15 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-7011, E-MEXP-2657, E-GEOD-20504, E-GEOD-22278, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-MEXP-1648, ... (30 experiments)

individual id
studied in E-GEOD-19519

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-MEXP-561, E-GEOD-360

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22152, E-GEOD-1493, E-GEOD-21750, E-MEXP-1412, ... (8 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-19743, E-GEOD-19069, E-GEOD-3365, E-GEOD-7307, E-GEOD-16363 ... (5 experiments)

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Stimulus or stress
studied in E-GEOD-7538

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-20677, E-GEOD-16837, E-MEXP-973, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541, E-GEOD-4922

Processing time: 0.412 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM